Phase II trial of epirubicin at standard dose in relapsed ovarian cancer.
Peláez
I
I
Lacave
A J
AJ
Palacio
I
I
Alvarez
E
E
Cueva
J F
JF
Muñiz
I
I
Arranz
F
F
Fra
J
J
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D015251:Epirubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D015251:Epirubicin